AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
What does it do?
AstraZeneca is a British pharmaceutical giant that discovers, makes, and sells prescription medicines used by millions of people worldwide. Think of them as one of the companies behind the drugs your doctor prescribes for cancer, heart disease, and diabetes. You might recognise them from the COVID-19 vaccine they developed with Oxford University. Their drugs include treatments for lung cancer, blood cancer, and heart failure — serious, life-threatening conditions where patients often have no other good options.
AstraZeneca has transformed itself from a mid-tier drugmaker into one of the most valuable healthcare companies on the planet, nearly doubling its revenue in just a few years through a wave of blockbuster cancer drugs. At a $271 billion market cap, it is the largest company listed on the London Stock Exchange, making it a bellwether for European pharma. Investors are watching closely because several of its newest drugs are still in early growth phases, meaning the revenue story may not be over yet.
How does it make money?
AstraZeneca makes money by selling prescription medicines to hospitals, pharmacies, and healthcare systems in over 100 countries. Their biggest revenue engine is oncology — cancer drugs like Tagrisso (lung cancer) and Enhertu (breast and lung cancer) generate billions annually, with Tagrisso alone bringing in over $5 billion a year. They also earn significant revenue from cardiovascular and kidney drugs like Farxiga, which has expanded beyond diabetes into heart failure treatment. Total revenue hit $58.7 billion in the latest year, up from $54.1 billion the prior year — that is nearly 9% growth for a company of this size.
Why do investors care?
The growth story here is pipeline depth — AstraZeneca has an unusually large number of drugs either recently approved or still in late-stage trials, which means potential new revenue streams for years to come. Their partnership with Daiichi Sankyo on antibody-drug conjugates (a cutting-edge way to deliver cancer treatment directly to tumour cells) is seen as a major competitive advantage. For the thesis to work, key drugs need to keep gaining market share, new approvals need to land, and the company needs to avoid major patent cliffs — the moment when a drug's patent expires and cheaper generics flood the market. With net income of $10.2 billion on $58.7 billion in revenue, profitability is strong, but execution must remain consistent.
Deep Dive
MemberA full investor briefing on AstraZeneca PLC — history, leadership, risks, and outlook.